Abstract:Human studies consistently identify bioenergetic maladaptations in brains upon aging and neurodegenerative disorders of aging (NDAs), such as Alzheimer's disease, Parkinson's disease, Huntington's disease, and Amyotrophic lateral sclerosis. Glucose is the major brain fuel and glucose hypometabolism has been observed in brain regions vulnerable to aging and NDAs. Many neurodegenerative susceptible regions are in the topological central hub of the brain connectome, linked by densely interconnected long-range axons. Axons, key components of the connectome, have high metabolic needs to support neurotransmission and other essential activities. Long-range axons are particularly vulnerable to injury, neurotoxin exposure, protein stress, lysosomal dysfunction, etc. Axonopathy is often an early sign of neurodegeneration. Recent studies ascribe axonal maintenance failures to local bioenergetic dysregulation. With this review, we aim to stimulate research in exploring metabolically oriented neuroprotection strategies to enhance or normalize bioenergetics in NDA models. Here we start by summarizing evidence from human patients and animal models to reveal the correlation between glucose hypometabolism and connectomic disintegration upon aging/NDAs. To encourage mechanistic investigations on how axonal bioenergetic dysregulation occurs during aging/NDAs, we first review the current literature on axonal bioenergetics in distinct axonal subdomains: axon initial segments, myelinated axonal segments, and axonal arbors harboring pre-synaptic boutons. In each subdomain, we focus on the organization, activity-dependent regulation of the bioenergetic system, and external glial support. Second, we review the mechanisms regulating axonal nicotinamide adenine dinucleotide (NAD+) homeostasis, an essential molecule for energy metabolism processes, including NAD+ biosynthetic, recycling, and consuming pathways. Third, we highlight the innate metabolic vulnerability of the brain connectome and discuss its perturbation during aging and NDAs. As axonal bioenergetic deficits are developing into NDAs, especially in asymptomatic phase, they are likely exaggerated further by impaired NAD+ homeostasis, the high energetic cost of neural network hyperactivity, and glial pathology. Future research in interrogating the causal relationship between metabolic vulnerability, axonopathy, amyloid/tau pathology, and cognitive decline will provide fundamental knowledge for developing therapeutic interventions.

Pathobiochemistry of Aging and Neurodegeneration: Deregulation of NAD+ Metabolism in Brain Cells

NAD+ metabolism and its roles in cellular processes during ageing

Targeting NAD Metabolism for the Therapy of Age-Related Neurodegenerative Diseases

Energy Metabolism Decline in the Aging Brain—Pathogenesis of Neurodegenerative Disorders

NAD+ homeostasis in health and disease

NAD metabolism: Role in senescence regulation and aging

NAD+ metabolism: pathophysiologic mechanisms and therapeutic potential

NAD+ Deficiency Is a Common Central Pathological Factor of a Number of Diseases and Aging: Mechanisms and Therapeutic Implications

The therapeutic perspective of NAD+ precursors in age-related diseases

NAD+ centric mechanisms and molecular determinants of skeletal muscle disease and aging

Nicotinamide Phosphoribosyltransferase as a Key Molecule of the Aging/Senescence Process

NADH: the redox sensor in aging-related disorders.

Axonal energy metabolism, and the effects in aging and neurodegenerative diseases

Implications of altered NAD metabolism in metabolic disorders

Nad(+) Metabolism and Nad(+)-Dependent Enzymes: Promising Therapeutic Targets for Neurological Diseases

Cytoplasmic and Mitochondrial NADPH-Coupled Redox Systems in the Regulation of Aging

Targeting NAD+ in Metabolic Disease: New Insights Into an Old Molecule

Implications of NAD+ boosters in translational medicine

NAD+ metabolism and therapeutic strategies in cardiovascular diseases

Evolving concepts in NAD+ metabolism

Vitamin B3, the Nicotinamide Adenine Dinucleotides and Aging